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Dendritic cells (DC) have been tested in cancer immunotherapy clinical trials for two
decades. Over this time, the methods of DC culture (or manufacture) have evolved, the
approaches for antigen loading have broadened, the maturation signals have varied and
different sites of administration have been tested.The post-vaccination immunologic ques-
tions asked have also varied between trials and over time. In this review, I will consider
multiple aspects of DC-based vaccines tested in cancer patients, including the cell culture,
antigen loading, maturation, and delivery, as well as what we have learned from testing
immune responses in vaccinated patients who have benefited clinically, and those who
have not measurably benefited.
Keywords: cancer vaccines, tumor immunology, antigen presentation, dendritic cells, antigen loading
INTRODUCTION
BEGINNINGS
Dendritic cells (DC) were first identified in the early 1970s (1).
However, the extremely low frequency of these cells in peripheral
blood and many tissues made experimentation with DC challeng-
ing. General agreement on cell surface markers to uniquely identify
“DC” from other myeloid lineage cells was another early hurdle in
the field that was surmounted (DC are, at a minimum, large, gran-
ular lymphocytes that are MHC class I, MHC class II, and CD86
high, Figure 1). The more widespread investigation of DC identity
and biology, and subsequent clinical testing of DC-based vaccines
required methods for small and large-scale culture and expansion
of DC progenitors in vitro (2). Methods were initially identified
for expanding DC from human peripheral blood monocytes with
granulocyte-macrophage-colony stimulating factor (GM-CSF) (3,
4) and eventually, similar approaches and surface markers were
found that could be utilized for both human and murine systems.
After these advances, the field was wide open.
In one of the earliest trials, Mukherji et al. (5) used intradermal
injection of MHC class I-restricted MAGE-1 peptide-pulsed and
GM-CSF-cultured monocytes to treat three HLA-A1+ patients
with advanced metastatic melanoma. They observed autologous
melanoma-reactive and peptide-specific CD8+ T cell responses,
but no significant therapeutic responses. Such very early clinical
results supported the safety and immunologic activity of these cells
in cancer patients.
FIRST GENERATION CLINICAL TRIALS
The early clinical trials of DC-based cancer immunotherapy estab-
lished the general safety and feasibility of this cancer vaccine strat-
egy, and its lack of toxicity compared with other cancer treatment
approaches (e.g., chemotherapy, radiation). Importantly, a small
number of positive clinical responses and the clear demonstration
that the goal of anti-tumor immune activation was achieved, bol-
stered the field, and supported additional trials. There have been
several recent DC vaccine reviews published that are excellent, and
that give additional details (6–8). The few early trials highlighted
below are important, but small, and did not utilize standardized
manufacture procedures throughout the clinical trial.
One of the first reported clinical trials that described the abil-
ity of tumor antigen-pulsed DCs to elicit a tumor-specific T cell
response and yield a clinical response was published by Hsu et al.
(9). In this study, four patients were treated with low-grade follic-
ular B-cell lymphoma resistant to chemotherapy. The DCs were
pulsed with target antigens of clonal immunoglobulin (idiotype)
expressed by the non-Hodgkin’s lymphoma, a tumor-specific,
unique antigen. Patients were immunized with DC followed by
booster injections of idiotype protein and keyhole limpet hemo-
cyanin (KLH, as an immunogenic xenoantigen as well as heterol-
ogous “help” to activate CD4+ T cells) as well as a final DC boost
infusion given 5–6 months later. All four patients developed cellu-
lar proliferative responses specific to their own idiotype protein.
More importantly, one patient had a complete tumor regression, a
second patient had a partial regression, and a third patient resolved
all evidence of disease. This very small study was an important
proof of principal for the clinical potential of DC vaccines.
While the study performed by Mukherji et al. (above) evalu-
ated monocyte-derived antigen presenting cells (APC), it may not
have formally tested a more fully differentiated DC because the
culture contained GM-CSF, but it lacked IL-4. The first clinical
trial using the monocyte-derived DC that have been most com-
monly used in clinical trials (including both GM-CSF and IL-4
in the monocyte precursor culture) was performed by Nestle et
al. (10). Sixteen melanoma patients were treated using autologous
monocyte-derived DC pulsed with a cocktail of gp100, MART-
1, tyrosinase, MAGE-1, or MAGE-3 peptides chosen to suit the
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individual patient’s class I HLA molecules. In addition, DC pulsed
with autologous tumor lysate were used to treat another four
patients. To provide antigen non-specific CD4+ T cell-mediated
help for the CD8+ T cells, KLH was included during antigen
pulsing. DC were injected directly into uninvolved lymph nodes.
Patients received 6–10 injections of 1× 106 cells every 1–4 weeks.
Tumor regression was seen in 5 of the 16 patients, including
two complete responses lasting over 15 months. Tumor regres-
sions occurred in skin, soft tissue, lung, and pancreas indicating
an impact on the clinical course of metastasizing melanoma,
regardless of metastatic site.
As with many of the early trials (examples here and others), a
variable number of DC vaccine administrations, consisting of dif-
ferent cell numbers and boost injections were delivered, and mul-
tiple types of antigen loading strategies were used. These earliest
clinical studies were more proof of principle for the in vivo activity
of DC, and less a formal testing of a specific DC vaccine approach.
In another melanoma clinical trial, Banchereau et al. (11) evalu-
ated immune and clinical responses in 18 patients with metastatic
melanoma after injecting DCs pulsed with peptides (MART-1,
tyrosinase, MAGE-A3, and gp100) subcutaneously. They utilized
CD34+ hematopoietic progenitor cells as an alternative source of
DC. DC were administered in a dose-escalation design. Enhanced
antigen-specific immune responses to at least one of the peptides
were seen in 16 or 18 patients, and 6 of 7 patients with immunity to
two or fewer antigens had progressive disease after the study ended,
while only 1 of 10 patients who responded to more than two anti-
gens had tumor progression. This larger and more standardized
study showed that broad immune responses to multiple tumor
antigen-derived peptides correlated with better clinical outcome,
one of the first studies showing that statistically significant corre-
lation between immunity induced from DC vaccines and clinical
outcome.
It is clear from the clinical trials described above, that most
clinical trials are unique, they involve individual patient vaccina-
tion approaches and single clinical trial arms, and it is difficult
to compare them. Monocytes and CD34+ progenitors; com-
plex tumor lysates containing normal, tumor-associated/shared
and tumor-specific/private antigens, or synthetic MHC class I-
restricted peptides; injection into blood (i.v.), skin (s.c. or i.d.),
or lymph nodes (i.n.); are all parameters playing unclear roles
in any clinical responses seen (Figure 2). The initial lessons
learned were simply that DC-based vaccines were safe, feasible,
and had the potential to promote clinically significant tumor
regressions.
LIMITED CLINICAL RESULTS FOR DC-BASED VACCINES
In 2004, Rosenberg et al. published an article on the state of active
specific immunotherapy cancer trials (12). They analyzed 9 years
of data (1995–2004), essentially all of the early, or“first generation”
trials. Overall, they reviewed 1,306 solid tumor patients using the
modified Response Evaluation Criteria in Solid Tumors (RECIST)
in which clinical response is defined as at least 50% reduction
in the sum of the products of the perpendicular diameters of all
lesions without 25% growth of any lesion or the appearance of new
lesions. With an overall therapy-induced tumor regression rate of
only 3.3% in patients vaccinated with synthetic peptides, “naked”
FIGURE 1 | Common DC vaccine phenotypic and functional
assessments. The diagram shows the most common identity (flow
cytometric phenotyping) and potency (cytokine production) tests
performed.
FIGURE 2 | DC vaccine loading and administration approaches that
have previously been tested in clinical trials, and which are still being
investigated today.
DNA, peptide-pulsed DC, recombinant vaccinia viruses, recom-
binant fowlpox viruses, or recombinant adenoviruses expressing
various tumor-associated antigen (TAA), the results were grim for
vaccine approaches in general. Of these immunization methods,
peptide-pulsed DCs seemed to be the most effective strategy, with
7.1% of treated patients exhibiting tumor regression. While this
frequency of response was higher than those frequencies found for
other vaccination strategies, the clinical response was still low.
DC VACCINE COMPLEXITIES
Unlike chemotherapy, immunological vaccines have not followed
a linear dose-response effect. Instead, because immunologic vac-
cines depend on the complex interactions of a large number of
variables, many of which are difficult to test: (1) the administration
route (s.c., i.d., i.v., i.n., and more recently, intra-lymphatic, i.l.),
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(2) minimum immunogenic dose, (3) higher dose effects, (4) vac-
cination schedule (weekly, monthly, or multiple times in a week
or month), (5) immunological adjuvant type, and (6) the exist-
ing state of host immunological competence. There have been
attempts to make “immune competence” a criterion for trial
enrollment. A standardized skin test to recall antigens like tetanus
and mumps was investigated, but the results were unrelated to vac-
cine immune response. Better measures of “immune health” are
under investigation (13) but there are no clear definitions to date
that might serve to identify patients who are most likely to bene-
fit. Any alterations of these many variables can impact the patient
immunologic as well as clinical outcome following therapeutic
immunization.
The majority of patients treated in these earlier studies were
late-stage metastatic patients that were heavily pretreated with
conventional chemotherapeutic drugs prior to immunizations.
Not only do late-stage tumors have potent immune-inhibitory
functions well established both in the tumor microenvironment
and systemically, but many traditional chemotherapies have also
been shown to non-specifically decrease the number of leuko-
cytes in recipients, making metastatic patients severely immune-
compromised. Such patients would also be expected to have mul-
tiple tumor resistance mechanisms in place (e.g., infiltrated regu-
latory T cells, myeloid-derived suppressor cells, and other imma-
ture and skewed macrophages, immuno-inhibitory cytokines, and
genetic heterogeneity in tumor subclones). Assessment of tumor
infiltration and inflammation is being investigated as a bio-
marker for responsiveness to not only vaccines, but also other
immunotherapy approaches and traditional cancer treatments
(14, 15), but these areas of investigation are relatively recent and
still being validated.
There are several other possibilities to explain the poor clinical
response to these vaccines. The immune system, while potentially
effective, is limited by the frequency of responders that can be
stimulated by vaccinations. Even if TAA-specific responses were
stimulated by immunization, it is possible that the bulk tumor
mass was too large at the time of treatment for the available effec-
tor T cell population to infiltrate it and eliminate it efficiently.
It is also possible that while the vaccine-targeted antigens are
expressed by the tumors, their derivative peptides are not present-
ing on the cell surface in the context of MHC class I molecules,
making the tumor cells effectively invisible to CD8+ T cell recog-
nition. Tumors can down-regulate antigen processing machinery
molecules, including β-2-microglobulin (16, 17). Another possi-
bility is that TAA used for vaccinations were not expressed by
targeted tumors because metastatic deposits do not necessarily
express the same repertoire of antigens as the primary tumor or
that TAA-derived peptides used were not effective at eliciting high-
avidity T cell responders. This heterogeneity has been observed in
melanoma (18). The highest avidity T cells specific for self antigens
may have been deleted during the development of the immune
system by normal negative selection. Therefore, for some patients
treated in early DC vaccine trials, instead of receiving a vaccine
tailored to the individual patient’s TAA repertoire, these individu-
als may have been treated with arguably irrelevant non-presented
or weakly immunogenic antigens that led to a clinically meaning-
less immune response. Vaccines targeting only CD8+ T cells, with
short MHC class I-restricted peptides, may have only been able
to activate “helpless” CD8+ T cells with functional defects (19).
Lastly, some tumors have evolved cell-autonomous resistance to
immune-mediated killing.
SOURCES OF TUMOR ANTIGEN: IMMUNE TARGET COMPLEXITIES
Tumors are not homogenous tissues that can be effectively treated
with a single antigen epitope vaccination tactic. Tumors vary in
physiological location (primary tumor sites and metastatic sites),
TAA repertoire, vascularization, surrounding stroma, and other
properties. Some tumor types are considered more “immuno-
genic” due to spontaneous immune infiltration and have, there-
fore, been an early focus for many DC-based immunotherapy trials
(melanoma, renal cell cancer). These variations in tumor biology,
immune infiltration, and microenvironment biology are observed
between patients, the tissues affected, and at different time points
in the malignant process. For example, when considering inclu-
sion criteria, “stage IV cancer patients” are not a homogeneous
group. Whether patients with brain metastases can be included,
or those with LDH levels above normal limits must be consid-
ered, as immunotherapy vaccine clinical responses can need time
to evolve, and not all clinical settings are expected to allow for
immune response evolution.
When considering autologous tumor-based immunization
strategies, there are types of cancer that are not generally sur-
gically removed (pancreatic cancer, hepatocellular cancer treated
with ablative techniques), so the ability to load DC with autologous
tumor as a source of all potential public and private TAA may not
be feasible. Established cell lines are an immortal source of anti-
gen, but may have limited antigenic overlap with a specific patient’s
tumor. Cell lines may express a few known, shared TAAs, however
they may not express any tumor-specific and/or mutated/private
antigens that the patient’s tumor expresses and which may be crit-
ical to clinical outcomes. Similarly, some tumor types may have
only a few characterized shared TAA with even fewer well-defined
HLA-matched peptide epitopes. Importantly, since the expression
of TAA is not uniform among tumor cells and metastases, it may
be critical to co-administer several antigens, rather than a single
one, to avoid the possibility that the sole TAA will prove non-
immunogenic or that its epitopes may not be adequately presented
on the tumor cell. A long term goal in the field has been to iden-
tify the “best” TAA for targeting with vaccines. The optimal TAA
would be critical to survival of the tumor cells, expressed at distant
metastatic sites (not downregulatable), specific to the tumor (not
expressed on normal tissues), and immunogenic. Characterized
TAA were ranked by a group of experts (20), but the ideal, defined,
shared targets have not been identified for many tumor types, and
there remains some disagreement in the field exactly what type of
antigen should be targeted.
TECHNICAL ISSUES AND REMAINING QUESTIONS
REGARDING DC VACCINES
MATURATION
An early lesson learned in DC vaccine development was that the
DC obtained after 5–7 days of culture with GM-CSF+IL-4 were
not in an optimal state for T cell activation. These DC were subse-
quently referred to as“immature” and potentially tolerogenic until
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triggered by a pathogen and/or inflammatory signal. Such signals
serve to upregulate antigen presentation and co-stimulation mole-
cules and function, and reduce antigen uptake. Early cocktails were
sometimes donor-specific and undefined (monocyte-conditioned
medium), weakly stimulatory (TNF), or contained molecules
which were subsequently shown to have some negative effects
(PGE2). Currently employed cocktails can incorporate specific
pathogen-derived molecules, toll-like-receptor ligands (TLRs) and
other “type 1” skewing agents including interferons (21). Con-
versely for clinical settings other than cancer, immune suppressive
cocktails can be used to push DC toward their tolerizing capa-
bilities, for autoimmune or transplantation settings. For example,
anti-sense oligo co-culture of DC with anti-sense CD80, CD86,
and CD40 for treatment of autoimmune diabetes has been tested,
or DC culture with vitamin A for inhibition of transplant-specific
immunity is being developed (22, 23). Overall, as environmental
sensors, DC can be significantly modulated by instructions deliv-
ered by maturation signals and optimal signals for DC vaccines
are still being developed.
DOSE AND ROUTE
Many new therapeutic drugs are tested for the effective, maximum
tolerated, and toxic doses in early clinical trials. Their routes of
administration are often intravenous for quick dissemination to
many anatomic sites. DC vaccine development has not yet shown
significant toxicity at any dose delivered (24, 25), and there have
been few suggestions of minimum required dose. Doses are largely
defined as the “maximally feasible dose” from a blood draw or
leukapheresis procedure of a specific duration (90 min to 4 h).
Regarding route of delivery, many options have been tested and
questions remain, each has positive and negative aspects to con-
sider. For intradermal delivery, too many DC in a small volume
might die in situ. Intra-nodal delivery may deliver the DC to an
optimal site, unless they are not injected into a cellular region and
are injected in fat or stroma instead (26). Intravenous delivery may
send cells to lungs and liver and not secondary lymphoid tissues.
Not all tumors are accessible for intra-tumoral injection (which
has been tested with unloaded DC to allow DC to directly sample
TAA), and that environment might be harsh and result in quick
loss of DC function or viability in vivo. Intra-lymphatic delivery
may also be immunologically ideal (like intra-nodal), but is clini-
cally challenging to administer. The optimal DC vaccine dose and
route also remains to be established for human clinical trials.
SECOND GENERATION TRIALS AND LESSONS LEARNED
A new generation of clinical trials was conducted from 2004 to
2012, testing new hypotheses based on the lessons learned from
the first generation, proof-of-principle studies. One key area of
change has been the use of defined, optimized cytokine cock-
tails and pathogen-derived agonists to mature DC. The individual
constituents of these cocktails have an important impact on DC
biology, including the relative level of cell surface molecules (e.g.,
co-stimulatory molecules CD80, CD86, or maturation markers
CD83 or CCR7), the amount, timing, and duration of cytokine
production by DC (e.g., IL-12p70, IL-12p40, IL-10), DC lifespan,
and the trafficking potential and response to chemokine gradi-
ents (21). Early, high level production of IL-12p70 may not be
as optimal for T cell activation in vivo as delayed IL-12 produc-
tion until after DC have arrived from the site of injection to the
lymph node. Newer DC vaccines are not simply “mature” by a
few phenotypic markers, but are treated to elicit specific types
of “maturity” or immunologic skewing, based on culture condi-
tions, and planned antigen loading and injection route strategies.
Some trials testing more optimal cocktails have been performed
and published results should be available soon. Other cytokine
culture conditions have been tested in vitro [with IL-15 or IL-13
(7, 8)] but access to clinical grade reagents has been a limita-
tion until more relaxed guidelines from the US FDA, at least
for the earliest stage trials (“Guidance for Industry: CGMP for
Phase I Investigational Drugs” http://www.fda.gov/downloads/
Drugs/GuidanceComplianceRegulatoryInformation/Guidances/
ucm070273.pdf).
Shorter duration of DC cell culture (2–3 days instead of 5–
7 days with different DC maturation triggers has also been tested
(27). It is difficult to identify superior DC in vitro given that DC
differentiation may not be fixed once the DC are administered,
and very few randomized trials have been performed which com-
pare different DC in vivo. This also leads to one of the major
limitations in DC trials. The size of most trials is quite small and
hence, there are not multiple trial arms to compare experimen-
tal groups and learn the answers to important questions (with
any statistical confidence). Even when trials are “negative,” show-
ing minimal positive clinical effects, there are still many variables
which might explain weak results, including unavoidable patient–
patient variation in generation of an autologous cellular product,
and insufficient funding available to run larger, randomized trials
testing specific variables, like maturation cocktails, antigen choice,
antigen loading, dose, and route (28).
A blow to the field was the result of the randomized Phase
III trial comparing DTIC chemotherapy for melanoma (which
has a very poor efficacy record) with a matured, peptide-pulsed
DC vaccine (29). The trial was stopped early due to lack of dif-
ferences between the trial arms, which had similar overall clinical
response rates of<6%. Many of the variables discussed above have
been hypothesized to have played a part in the disappointing DC
vaccine results, including DC vaccine quality and consistency in
manufacture between different manufacturing sites, site of deliv-
ery (s.c. instead of i.d.), and lack of tumor-specific helper epitopes
or heterologous help to promote CD4+ T cell activation. With so
many open questions on how best to prepare DC vaccines, there
are still many possible causes for minimal clinical responses.
However, there have been a number of more successful trials
published in this period. Objective clinical responses and signifi-
cant immunologic responses were observed in a trial in renal cell
carcinoma patients testing Muc-1 peptide+heterologous PADRE
pulsed DC (s.c.) (30). These DC vaccines were combined with low
dose IL-2. In another study, acute myeloid leukemia patients in
remission from previous standard therapy receiving WT-1 mRNA-
loaded DC vaccines showed immune activation and improved
clinical outcomes (31). Another trial tested DC-tumor fusions in
myeloma patients before or after autologous stem cell transplant,
and observed both anti-tumor immune activation and reduction
of disease (32). Interestingly, these trials all employed a DC vaccine
combination strategy.
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NEXT GENERATION TRIALS: WHERE ARE WE GOING?
DC FOR CANCER PREVENTION?
A new clinical setting for tumor antigen vaccination has been pro-
posed, focused on prevention of cancer development in high risk
patients without current disease (33). This vaccination setting was
recently reported for a Muc-1 peptide-based vaccine in subjects
with advanced colonic adenomas (but not yet colorectal cancer).
The results showed that the peptide vaccine was immunogenic in
43% of the subjects and response was inversely correlated with
circulating MDSC levels (34). A related Muc-1 vaccine improved
survival in a murine model of colitis-associated colorectal can-
cer (35), supporting the further testing of preventative cancer
vaccination, including utilizing DC, in a prevention setting.
ANTIGEN LOADING
For antigen loading, peptide-pulsing, transfection/transduction,
and protein-pulsing continue to be used, as well as tumor lysate
loading. The procedure followed for tumor lysate preparation has
recently been examined. The simplest approach has been multi-
ple rounds of freezing (in a dry ice/ethanol bath or at −80°C)
and thawing (by 37° water bath). This procedure can break open
cells in a manner mimicking necrosis and allow subsequent tumor
protein isolation. However, there are other approaches. Tumor cell
exposure to UV and gamma irradiation has been shown to mimic
apoptosis, which delivers different signals to DC than necrotic
cells. Recently, tumor treatment with hypochlorous acid before
lysate purification was tested (36), and this method of oxida-
tion and rapid necrosis may be superior for DC vaccine loading.
Another important element may be the changes in tumor antigen
expression when tumors are cultured in hypoxic conditions (5%
instead of 20%) specifically mimicking in situ hypoxic tumor oxy-
gen levels (37). Such improved antigen preparation approaches
may yield improved clinical outcomes.
ROUTE OF DELIVERY
Based on data demonstrating that DC vaccines delivered intrader-
mally (i.d.) show very low level (<2%) migration to lymph nodes
(based most often on 111In-labeling (38, 39), and that ultrasound-
guided intra-nodal delivery has a risk of the vaccine being injected
into fat instead of a cellular area (26), other routes of delivery have
been tested. The results have varied between mice and humans,
and in patients, and all tested routes of delivery have proven to
be immunogenic in terms of T cell response induction. With-
out higher rates of objective clinical responses, identification of
superior routes of delivery remain unknown. Thus far, there has
also been no strict correlation between phenotypic measures, like
CCR7 level on the DC surface (40), and subsequent migration.
There are suggestions that the maturation cocktail used impacts
migration (40) but there are no definitive answers yet. More
recently, newer MRI-based DC vaccine labels have been tested
(41) (D. Bartlett and P. Kalinski, personal communication, 2013)
and prolonged, semi-continuous intra-lymphatic delivery of DC
has been tested [(42), and P. Kalinski, personal communication,
2013]. Continued efforts at tracking DC migration in vivo and
optimizing routes of delivery may yield more potent DC vaccines.
A few such DC trials are underway.
SUPPRESSIVE DC
While the cancer and infectious disease communities have inves-
tigated optimally immune stimulating DC, the organ transplan-
tation and autoimmunity fields have sought approaches to either
maintain an “immature” DC status, or differentiate DC toward a
tolerogenic or immune suppressive activity. Such strategies include
pulsing DC with anti-sense oligonucleotides for co-stimulatory
molecules CD40, CD80, and CD86 to downregulate these mol-
ecules (22) for prevention and treatment of diabetes, or culture
with vitamin D3 and IL-10 for allograft tolerance (23). A recent
Phase I clinical trial testing anti-sense CD40/80/86 oligo pulsed
DC in type 1 diabetic patients showed that the cells were safe,
well-tolerated, and resulted in a reduction in a subset of B cells
(22). In recent preclinical primate modeling of kidney allograft
survival, i.v. infusion of vitamin D3/IL-10 regulatory DC was also
safe and resulted in significantly improved allograft survival (23).
Further clinical development of these strategies are underway.
DC VACCINE COMBINATIONS
The field of cancer immunotherapy is now in the position of
having more effective drugs encompassing not only vaccines in
development, but small molecule inhibitors of key signal transduc-
tion pathways and immunologic checkpoint inhibiting antibodies.
While all of these modalities, like the traditional standards of care
(surgery, chemotherapy, radiation) have strengths and weaknesses,
the current generation of clinical trials focuses on combinations
of these approaches. DC vaccines may have limitations as stand-
alone therapeutics, but in combinations they could play a role in
initiating and boosting anti-tumor immunity, promoting in vivo
cross-presentation, and promoting long term immunologic mem-
ory. Cytotoxic treatments can have multiple positive effects on the
immune system, from simple release of tumor antigens as can-
cer cells die, to cytotoxic agent-specific effects. Release of tumor
antigens allows endogenous DC to take up and present them,
or for larger numbers of tumor bed injected DC to take up the
broad array of released tumor antigens for T cell activation. Cyto-
toxic agent-specific immune effects can include: upregulation of
immune stimulatory molecule expression on tumor cells (e.g.,
DAMPs), increased tumor antigen expression, reduced suppres-
sor cells frequencies, as well as increased CTL proliferation and
activation. The pioneering studies in this area have largely been
performed in murine models, but the immune-promoting effects
of non-immune-based therapeutics are now being assessed in clin-
ical trials. Future DC vaccine combinations with rationally chosen
agents may increase the effectiveness of DC vaccines (43, 44).
DC TRANSCRIPTOME ANALYSIS
An important technological breakthrough has been the ability
to test the DC vaccine transcriptome. This detailed molecular
characterization allows for a broader understanding of DC vac-
cines. Manufacturing conditions, different maturation cocktails
(45, 46), and their impact on DC biology, over and above even a
very thorough examination of DC surface phenotype and cytokine
production (47) can be examined on a molecular basis. To date,
surface expression of standard DC markers (CD80, CD83, CD86,
MHC class I, MHC class II, CCR7) has not correlated significantly
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with in vivo vaccine effects. The type-1-skewing cytokine pro-
duced by DC, IL-12p70, is actively being investigated as a potency
assessment, based on its significant correlation with clinical out-
come was demonstrated (48). This assay was employed after it
was standardized for both spontaneous and induced expression
of IL-12p70 heterodimers (47). Transcriptome analysis allows
for a much broader assessment of DC vaccines, and may prove
informative for predictive biomarkers of immune and/or clinical
response. Such profiling has identified a type-1-skewing genetic
profile expressed by DC matured with IFNγ+LPS (45), and a list
of candidate genes that may be helpful for identity, stability, and
potency measures of DC vaccines (46). This approach may also
identify patient-to-patient variation of immunologic significance.
IMMUNOLOGIC MONITORING
Each DC vaccine clinical trial is based on the hypothesis that opti-
mal tumor antigen presentation will promote clinically effective
anti-tumor immunity. Understanding the effects of the vaccines
on each patient’s immune system is of utmost importance in mov-
ing the field forward. Most trials examine effector T cells activated
by antigen-pulsed DC, but the cross-talk between DC and innate
immune cells may also be mechanistically very important. Vaccine
cell interaction with innate immune cells is expected to be vari-
able with different types of DC cultured and loaded in different
ways. DC modulation of suppressor cells, like regulatory T cells
and myeloid-derived suppressor cells, may occur, and the over-
all immune effects may vary in magnitude and quality between
peripheral blood and the tumor site. Some studies have found
similar results in blood and tumor, while others have not, and
studies examining DC vaccine effects at the tumor site are limited.
Obtaining tumor biopsies can be challenging but well is worth the
difficulties in order to understand the direct tumor site impact.
Larger sized DC trials may involve multiple clinical sites, as well as
vaccine manufacture sites, which necessitates careful standardiza-
tion of blood processing vaccine culture and immune monitoring
assay methodologies (49) as well as data reporting (50). Despite
the technical challenges, careful immunologic monitoring, partic-
ularly with multiple functional assays, yields critical mechanistic
insights.
CONCLUSION
Yes, we are making progress in the DC vaccine field. A more
rational, defined, and data-driven approach is being employed in
culturing, maturing, and antigen loading of DC (51). Fully char-
acterizing DC vaccine transcription profiles moves far beyond the
limited cell surface phenotypes previously employed. Performing
more standardized trial designs where patients receive the same
type of vaccine reduces variables to patient-to-patient variation
instead of adding variables and may identify the most critical vac-
cine parameters to carry forward. More thorough, robust and
standardized immune monitoring assessments are allowing to
field to draw more meaningful conclusions from each trial. In
the future, the next generation of optimized vaccines identified
may selectively be used for individual patients, based on their
tumor biology. A new generation of DC vaccine trials are under-
way (52) which have the potential to move this area of personalized
medicine forward.
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